Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Noemie Luong

Noemie Luong

Associate Principal Scientist, Translational Pharmacology Debiopharm

Seminars

Monday 12th October 2026

Evaluating Preclinical Performance of Novel Linker-Payloads to Widen ADC Therapeutic Index

12:00 pm

Explaining the impact of ADC innovation to improve and widen therapeutic index and potentially maximize patient benefit
Laying out MultiLINK novel linker-payload preclinical performance and mechanistic characterization to understand effect on tumor cells
Contextualizing novel linker-payload preclinical proof-of-concept to enhance ADC tolerability and therapeutic index

Noemie

View all Speakers

View Event Brochure